Novo will reduce the list price for NovoLog and NovoLog Mix 70/30 by 75%, and cut Novolin and Levemir’s list prices by 65% — but not until 2024.
Novo Nordisk A/S, one of the world’s biggest makers of insulin, said it would cut US prices for several of its products by up to 75%, following similar actions by rival Eli Lilly & Co.
Novo will reduce the list price for NovoLog and NovoLog Mix 70/30 by 75%, and cut Novolin and Levemir’s list prices by 65%, according to a statement Tuesday. It is also reducing the list price of several unbranded insulins. The changes go into effect in 2024. Lilly said earlier this month that it would slash prices for Humalog and Humulin by 75% and cap out-of-pocket costs at $35. Those actions were hailed by President Joe Biden, who said then that other companies would follow suit.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk plans to cut insulin prices in U.S. by up to 75%Drugmaker Novo Nordisk said on Tuesday it would cut list prices for several insulin drugs by up to 75% in the United States, starting Jan. 1, 2024.
Read more »
WSJ News Exclusive | Novo Nordisk to Slash Insulin Prices by Up to 75%Breaking: Novo Nordisk, a large insulin maker, plans to cut the prices of its widely used products up to 75% to make them more affordable for patients. This follows a similar move by Eli Lilly.
Read more »
Novo Nordisk Will Cut Insulin Cost in U.S. by Up to 75 PercentNovo Nordisk will slash the list price of several of its insulin drugs by as much as 75 percent, the company said Tuesday.
Read more »
Following Eli Lilly, drugmaker Novo Nordisk announces cuts to insulin pricesBREAKING: Novo Nordisk says it will lower the U.S. list price of some of its insulin products by up to 75% starting Jan. 1, 2024, following a similar move by Eli Lilly.
Read more »
Novo Nordisk to lower prices of some insulins, following similar move by LillyNovo Nordisk said that it is lowering the prices of several insulin products by up to 75% starting in 2024. The company’s U.S.-listed shares were up about...
Read more »